Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06066138CT.gov A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alveolar Soft Part Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Tivantinib | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | P2 | B |
| Crizotinib | European Organisation for Research and Treatment of Cancer - EORTC | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Temsirolimus | National Cancer Institute (NCI) | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Vismodegib | National Cancer Institute (NCI) | P1/2 | CCC |
| Zoledronate | University of Florida | P1/2 | CC |
| GVAX | Dana-Farber Cancer Institute | P1 | CC |
+14 more in the Alveolar Soft Part Sarcoma cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- TivantinibArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)B
- CrizotinibEuropean Organisation for Research and Treatment of Cancer - EORTCB
- CixutumumabNational Cancer Institute (NCI)B
- TemsirolimusNational Cancer Institute (NCI)B
- CabozantinibNational Cancer Institute (NCI)CCC
Citation
Floatz Terminal. Atezolizumab in Alveolar Soft Part Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-alveolar-soft-part-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →